92 related articles for article (PubMed ID: 26040053)
1. Autoimmune hepatitis and allergic reactions during anti-TNFα treatment.
Atzeni F; Sarzi-Puttini P
Isr Med Assoc J; 2015 Apr; 17(4):247-8. PubMed ID: 26040053
[No Abstract] [Full Text] [Related]
2. Autoimmune hepatitis triggered by adalimumab and allergic reactions after various anti-TNFα therapy agents in a patient with rheumatoid arthritis.
Petríková J; Jarčuška P; Svajdler M; Pella D; Macejová Z
Isr Med Assoc J; 2015 Apr; 17(4):256-8. PubMed ID: 26040057
[No Abstract] [Full Text] [Related]
3. Autoimmune hepatitis concomitant with hypergammaglobulinemic purpura, immune thrombocytopenia, and Sjögren's syndrome.
Wada M; Kamimoto H; Park SY; Shintani S; Nakasho K
Intern Med; 2001 Apr; 40(4):308-11. PubMed ID: 11334390
[TBL] [Abstract][Full Text] [Related]
4. Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome.
Steinfeld SD; Appelboom T; Delporte C
Arthritis Rheum; 2002 Aug; 46(8):2249-51. PubMed ID: 12209534
[No Abstract] [Full Text] [Related]
5. Aquaporins in primary Sjögren's syndrome: comment on the articles by Steinfeld et al.
Waterman SA; Beroukas D; Hiscock J; Jonsson R; Gordon TP
Arthritis Rheum; 2003 Apr; 48(4):1167-8. PubMed ID: 12687572
[No Abstract] [Full Text] [Related]
6. Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor α agents.
Efe C; Purnak T; Ozaslan E; Wahlin S
Hepatology; 2010 Dec; 52(6):2246-7. PubMed ID: 20715094
[No Abstract] [Full Text] [Related]
7. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles.
Ettefagh L; Nedorost S; Mirmirani P
Arch Dermatol; 2004 Aug; 140(8):1012. PubMed ID: 15313825
[No Abstract] [Full Text] [Related]
8. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of Sjogren's syndrome with rituximab.
Touma Z; Sayad J; Arayssi T
Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
[No Abstract] [Full Text] [Related]
10. [Effect of prescriptions replenishing vital essence, tonifying Qi and activating blood on TNF-alpha, IL-1beta expressions in serum and submaxillary gland of NOD mice with Sjogren's syndrome].
Wu GL; Li TY; Pu XH; Yu GY
Zhongguo Zhong Yao Za Zhi; 2013 Feb; 38(3):413-6. PubMed ID: 23668020
[TBL] [Abstract][Full Text] [Related]
11. Infliximab and primary Sjogren's syndrome: comment on the article by Mariette et al.
Fresko I; Seyahi E; Yurdakul S
Arthritis Rheum; 2004 Dec; 50(12):4077; author reply 4077-8. PubMed ID: 15593208
[No Abstract] [Full Text] [Related]
12. [TNF-alpha inhibitors].
Fain O
Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
[No Abstract] [Full Text] [Related]
13. Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome.
Matsumoto T; Morizane T; Aoki Y; Yamasaki S; Nakajima M; Enomoto N; Kobayashi S; Hashimoto H
Pathol Int; 2005 Feb; 55(2):70-6. PubMed ID: 15693852
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
[No Abstract] [Full Text] [Related]
15. The therapy of Sjogren's syndrome: a review.
Coaccioli S; Giuliani M; Puxeddu A
Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
Pollard RP; Abdulahad WH; Vissink A; Hamza N; Burgerhof JG; Meijer JM; Visser A; Huitema MG; Spijkervet FK; Kallenberg CG; Bootsma H; Kroese FG
Ann Rheum Dis; 2013 Jan; 72(1):146-8. PubMed ID: 22851468
[No Abstract] [Full Text] [Related]
17. [Sjögren's syndrome: a new approach to treatment].
Rossier V; Bart PA; Spertini F
Rev Med Suisse; 2012 Apr; 8(337):843-7. PubMed ID: 22594008
[TBL] [Abstract][Full Text] [Related]
18. Recognition and management of Sjögren's syndrome: strategies for the advanced practice nurse.
Vale DL
Nurs Clin North Am; 2000 Mar; 35(1):267-78. PubMed ID: 10673580
[TBL] [Abstract][Full Text] [Related]
19. Will targeting B cells be the answer for Sjögren's syndrome?
Looney RJ
Arthritis Rheum; 2007 May; 56(5):1371-7. PubMed ID: 17469093
[No Abstract] [Full Text] [Related]
20. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
Carsons SE
Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
